Latest Administration News

Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.

Imugene Limited reported a significant 54% reduction in net loss for FY25, driven by cost efficiencies and promising clinical progress in its immuno-oncology pipeline. The company’s lead asset, azer-cel, achieved a 79% response rate in Phase 1b trials and secured FDA Fast Track designation.

EMVision Medical Devices is set to activate its sixth and final pivotal trial site at UCLA Health, advancing its emu™ brain scanner towards FDA submission. Meanwhile, the Continuous Innovation Study grows with the addition of Box Hill Hospital.

Holista Colltech has inked a binding supply and development agreement with US-based Regenerex Pharma to exclusively supply proprietary ovine collagen for advanced wound care products, targeting the lucrative US market initially with plans for global expansion.

Imricor Medical Systems reports significant regulatory approvals and clinical trial progress, positioning itself as a disruptive force in the growing electrophysiology market. With a strengthened commercial pipeline and solid cash reserves, the company is poised for a pivotal growth phase.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

The Australian Wealth Advisors Group Ltd (AWAG) reported a 13% revenue increase and a $1.2 million profit before tax in FY2025, driven by strategic Equity Partnership Scheme investments and a strong funds under management base.

GR Engineering Services Limited has announced a fully franked ordinary dividend of AUD 0.12 per share for the half-year ending June 2025, accompanied by a Dividend Reinvestment Plan offering a 2.5% discount.

FAR Limited reported a sharp turnaround to a $1.8 million loss in H1 2025, driven by a $6 million claim from Woodside Energy over its Senegal RSSD Project sale. The company continues negotiations amid volatile oil prices impacting its receivables.

Regal Partners Limited has announced a fully franked ordinary dividend of AUD 0.06 per share for the first half of FY25, alongside a dividend reinvestment plan open to Australian and New Zealand shareholders.

Neuren Pharmaceuticals has initiated the first US investigational site for its pivotal Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, marking a significant milestone in addressing this rare neurodevelopmental disorder.

Haranga Resources has secured regulatory approvals and begun underground works at its Lincoln Gold Project, setting the stage for a maiden drilling campaign aimed at upgrading a significant historical gold resource to JORC standards.